Remove 2020 Remove Medical science Remove Prospecting
article thumbnail

Journal Citation Reports 2022: A preview

Clarivate

Two novel events drove the 2020 data: the inclusion of Early Access content in the JCR for the first time, and the sudden appearance of COVID-19 as an entirely new, extremely urgent field of study. These factors made the 2020 data explored in last year’s release particularly unusual.

article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

However, access to these medicines is not close to meeting patient demand, creating inequalities in the health prospects of those diagnosed with cancer. He received an MD from the Georg August University of Göttingen and completed a postdoctoral Master’s in Medical Sciences Clinical Pharmacology at the University of Glasgow.

Patients 105
article thumbnail

Leveraging innate cell engagers for lymphoma treatment

European Pharmaceutical Review

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. Andreas held several senior executive roles, including Senior Vice President of Medical Sciences at ImClone Systems, Inc., later acquired by Eli Lilly and Company.